FDA Approves Restylane Kysse For Lip Agumentation

New Lip Filler Approved

The U.S. Food and Drug Administration (FDA) has approved Galderma’s Restylane Kysse for lip augmentation and the correction of upper perioral rhytids in adults over the age of 21. Restylane Kysse is a hyaluronic acid (HA)-based filler that lasts for up to one year and is indicated for people with lips that have changed due to the aging process or for those seeking natural-looking, fuller lips.

Phase 2 Results for Investigational Ready-To-Use Botulinum Toxin

Galderma Investigating Liquid, Ready to Use Botulinum Toxin

Galderma recently announced the Phase 2 clinical trial results for its novel ready-to-use investigational botulinum toxin, QM1114. The multicenter, randomized, double-blind, placebo-controlled study successfully demonstrated the safety and efficacy of QM1114, a liquid formulation of botulinum toxin type A, for the treatment of glabellar lines in more than 350 patients. According to a release from the company, the Phase 3 clinical trial program, which will include approximately 1,500 subjects, will begin soon to support regulatory submissions globally.

Galderma Celebrates Charitable Partnerships for Month of June

Patients undergoing treatment with Dysport during the month of June are helping to support three impactful charities thanks to a partnership between Galderma, Dress for Success, PAWS and The National Coalition Against Domestic Violence (NCADV).

Until June 30, for every Dysport aesthetic treatment administered in select markets nationwide from a licensed healthcare provider and recorded in the ASPIRE Galderma Rewards loyalty program, $25-$100 will be donated to Dress for Success, PAWS or the NCADV as follows:

Galderma Launches Joint Promotions With Top Skincare Brands

Woman looking at skin care

In an effort to encourage patient loyalty by helping practices offer science-based skincare products along with facial injectable treatments, Galderma Laboratories is collaborating with professional-grade skincare brands Revision Skincare, Alastin Skincare and Sente. This effort was inspired by the ongoing success of the company’s long-standing, ongoing collaborations with Colorescience and Mentor Breast Implants.

Results From Phase 4 Clinical Studies of Restylane Refyne and Restylane Defyne Released

Phase 4 Clinical Study Results on Restylane Refyne and Defyne

Galderma has released the results from two Phase 4 clinical studies of Restylane Refyne and Restylane Defyne, the most recent U.S. additions to it Restylane family of soft tissue fillers. The Natural Expression study found that natural facial expression was maintained in 95% (60/63) of subjects (primary objective). The Dynamic Strain study found that 83% (25/30) of subjects had enhanced attractiveness, looked younger and maintained expression following injections of Restylane Refyne and Restylane Defyne.

FDA Approves Restylane Refyne and Restylane Defyne Dermal Fillers

FDA Approves Restylane Refyne and Restylane Defyne Dermal Fillers

Galderma has received U.S. Food and Drug Administration (FDA) approval of two new Restylane products for the treatment of nasolabial folds (NLF) in patients over the age of 21. Restylane Refyne is approved for the treatment of moderate to severe facial wrinkles and folds, and Restylane Defyne for the treatment of moderate to severe, deep facial wrinkles and folds.